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This article describes a rapid UPLC-MS/MS method to quantitate novel bile
acids in biological fluids and the evaluation of their diagnostic potential in
Niemann-Pick C (NPC). Two new compounds, NPCBA1 (3b-hydroxy,7b-N-
acetylglucosaminyl-5-cholenoic acid) and NPCBA2 (probably 3b,5a,6b-trihy-
droxycholanoyl-glycine), were observed to accumulate preferentially in NPC
patients: median plasma concentrations of NPCBA1 and NPCBA2 were 40-
and 10-fold higher in patients than in controls. However, NPCBA1 concentra-
tions were normal in some patients because they carried a common mutation
inactivating the GlcNAc transferase required for the synthesis of this bile acid.
NPCBA2, not containing a GlcNAc moiety, is thus a better NPC biomarker.
Keywords: bile acids; Biomarkers; GlcNAc transferase; Niemann-Pick C;
screening; UPLC-MS/MS
Niemann-Pick C (NPC) is a severe autosomal recessive
lipid storage disorder that can give rise to liver disease
during infancy [1,2] and produce neurological dysfunc-
tion starting in childhood/early adult life. To date,
mutations in two genes have been identified: NPC1
(OMIM 607623), in ~ 95% of NPC patients, and NPC2
(OMIM 601015) in 5% [3,4]. Although the functions of
NPC1 and NPC2 proteins have not been completely elu-
cidated, their critical involvement in cholesterol export
from the lysosome/late endosomal cellular compartment
has been recognized [5–8]. Indeed, the abnormal traf-
ficking and metabolism of cholesterol evident in NPC
has proved to be useful in the diagnosis of the disorder.
Lysosomal accumulation of unesterified cholesterol can
be detected by filipin staining of cultured fibroblasts [9]
and cholesterol is converted into auto-oxidation
products (oxysterols; 7-oxocholesterol and cholestane-
3b,5a,6b-triol) whose levels are elevated in plasma [10–
15]. Filipin staining requires culturing of fibroblasts and
so is not a viable rapid screening test. For measurement
of oxysterols, blood needs to be taken into EDTA tubes
and the plasma needs to be rapidly separated. Delays
result in the ex vivo conversion of cholesterol to oxys-
terols with the potential for false positive results. Most
methods for oxysterol quantitation require derivatiza-
tion for analysis by liquid chromatography- (LC-MS) or
gas chromatography-mass spectrometry (GC-MS).
There is a need for a simple test using samples that are
Abbreviations
GC-MS, gas chromatography-mass spectrometry; LC-MS, liquid chromatography-mass spectrometry; NPC, Niemann-Pick C; SRM, single
reaction monitoring; UPLC-MS/MS, ultra performance liquid chromatography linked to a tandem mass spectrometer.
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easily sent to the laboratory such as dried blood spots
or plasma spotted onto paper – samples that can be sent
by post even from another country. This could be used
at the earliest stages of the disease process, for example,
infantile cholestasis or childhood splenomegaly, which
often precede the characteristic neurological symptoms,
including ataxia, vertical supranuclear gaze palsy, dysto-
nia and dementia [16–18]. In addition, a rapid and sim-
ple method could be used to screen patients with the
first hint of neurological dysfunction or psychiatric dis-
ease, a nonspecific presentation of NPC in adolescents
and adults that often remains undiagnosed and, conse-
quently, untreated for months or years [19,20].
A prompt diagnosis of NPC is important because,
in Europe, a licensed treatment (Miglustat) is available
for this disorder [21–23] and studies on animal models
indicate that early treatment offers the best chance of
limiting neurological damage [24]. Other treatments
for NPC are currently undergoing clinical trials (2-
hydroxypropyl-b-cyclodextrin [25], histone deacetylase
inhibitors [26] and arimoclomol).
We have investigated bile acids as potential biomark-
ers for NPC. Alvelius and coworkers, in 2001, demon-
strated the presence of a unique set of unusual bile acids
in the urine of a cholestatic infant with NPC [27]. These
were unsaturated C24 bile acids (5-cholenoic acids) with
a sulfated 3b-hydroxyl group, a 7b-hydroxyl group,
either free or conjugated with N-acetylglucosamine
(GlcNAc) and the C24 carboxyl group either free or
conjugated with glycine or taurine. The discovery in
2010, of increased production of 7-oxocholesterol in
NPC, probably as a result of free radical attack on accu-
mulating cholesterol [10], provided a possible explana-
tion for the origin of these ‘NPC bile acids’; they could
be produced by hepatic metabolism of 7-oxocholesterol,
probably via 3b,7b-dihydroxy-5-cholenoic acid and its
7b-N-acetylglucosamine conjugate. Subsequently, Mae-
kawa et al. developed methods for quantitation of three
NPC bile acids in urine, having synthesized the reference
compounds, 3b-sulfoxy-7b-N-acetyl-glucosaminyl-5-
cholenoic acid and its glycine and taurine conjugates
[28,29]. Initial results suggested that the urinary excre-
tion of these pooled metabolites was 400-fold greater
than controls. Unfortunately, further analyses have
shown overlap between NPC and controls, limiting the
use of the test in the diagnostic setting (M. Maekawa,
unpublished data). We considered a possible cause of
failure to detect the bile acids conjugated with N-acetyl-
glucosamine in NPC patients. A common homozygous
polymorphism/mutation in the UGT3A1 gene, c.T361G,
leads to an amino acid substitution (p.C121G) and
absence of activity of the encoded 7b-hydroxy bile acid
UDP N-acetylglucosaminyl transferase [30,31]:
homozygosity for c.T361G is present in about 20% of
Asian and Caucasian populations.
7-Oxocholesterol is not the only oxysterol produced
by nonenzymatic auto-oxidation of accumulating
cholesterol in NPC. Another oxysterol whose produc-
tion is greatly increased is cholestane-3b,5a,6b-triol
[10]. We reasoned that this oxysterol would probably
also be metabolized to a bile acid in the liver, produc-
ing an isomer of glycocholic and/or taurocholic acid.
Thus, we investigated the use of ultra performance liq-
uid chromatography linked to a tandem mass spec-
trometer (UPLC-MS/MS) to quantitate, in body
fluids, the following potential biomarkers for NPC: (a)
bile acids derived from 7-oxocholesterol (looking at
nonsulfated and sulfated bile acids for the first time)
and (b) an unusual isomer of glycocholic acid (proba-
bly derived from cholestane-3b,5a,6b-triol).
Materials and methods
Chemicals and reagents
Cholic acid (CA), chenodeoxycholic acid (CDCA),
ursodeoxycholic acid (UDCA), hyocholic acid (HCA), hyo-
deoxycholic acid (HDCA), deoxycholic acid (DCA), litho-
cholic acid (LCA) and the glycine and taurine conjugates of
these bile acids (GCA, TCA, GCDCA, TCDCA, GUDCA,
TUDCA, GDCA, TDCA, GLCA, TLCA) were purchased
from Steraloids (Newport, RI, USA)), and all the deuterium
labelled internal standards used (D4-CA, D4-CDCA, D4-
GCA, D5-TCA, D4-GCDCA and D4-TCDCA) were
obtained from CDN Isotopes (Pointe-Claire, QC, Canada).
HPLC-grade methanol was from Merck, water was puri-
fied using a Milli-Q system (Millipore UK Ltd, Watford,
ND, USA) and formic acid was from Fluka. 3b-Sulfoxy-
7b-N-acetyl-glucosaminyl-5-cholenoic acid and its glycine
and taurine conjugates were synthesized [28].
Instrumentation and experimental conditions
The UPLC-MS/MS instrument consisted of a Waters
ACQUITY UPLC coupled to a Xevo TQ-S triple quadru-
pole mass spectrometer with an electrospray ionization
source. The mass spectrometer was operated in negative
ion mode and data were acquired using MASSLYNX V4.1
software. Chromatographic separations were achieved using
a Waters ACQUITY UPLC™ BEH (Waters UK, Herts,
UK) C18 column (1.7 lm, 2.1 9 50 mm) maintained at
40 °C. Binary gradient profiles were developed using water
with 0.01% formic acid (A) and methanol (B) at a flow rate
of 500 lLmin1. Separations were conducted under the
following chromatographic conditions: 60% solvent A for
0.5 min, decreased to 1% over 1 min, maintained for 1 min
at 1% before being increased to 60% over 0.1 min.
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Column equilibration time was 0.9 min, with a total run
time of 3.5 min. The injection volume was 20 lL. Mass
spectrometric conditions were as follows: capillary voltage
2.7 kV, desolvation temperature 600 °C, cone gas flow
150 Lh1, desolvation gas flow 1200 Lh1, collision gas
flow 0.15 Lh1 and nebulizer gas flow 7 bar. Dwell time
was set as 3 ms for each analyte. The quantitation of the
different analytes was then performed using the single reac-
tion monitoring (SRM) parameters described in Table 1.
Preparation of stock solutions
Stock solutions of standard bile acids (50 lM) were pre-
pared in methanol before being combined and further
diluted into a series of working solutions, used for the cali-
bration standards (prior to the addition of the deuterated
internal standards, final concentration: 20 nM). Calibration
curves were plotted on the day of analysis across the con-
centration range of 0.1–250 nM for dried plasma and blood
spots, and 0.25–250 lM for urine.
Clinical samples
Plasma samples, stored at  80 °C, were available from previ-
ous NPC biomarker studies [32]. The NPC1 genotypes of the
patients included in the study are shown in Table 1 of the sup-
porting information. For seven of the NPC1 patients, exome
sequencing data were available, allowing determination of
their status with regard to the c.T361G (pC121G) mutation/
polymorphism in UGT3A1 (two homozygous for the muta-
tion, two heterozygotes and three wild-type). The samples
included untreated NPC1 patients (mutations listed in
Table S1), NPC1 heterozygotes and age-matched controls.
They were aged between 6 months and 54 years, with total
clinical score [20] between 0 and 35 and annual severity incre-
ment score (ASIS) [33] between 0 and 6.21. New plasma, blood
spot and random urine samples were obtained from patients
attending clinics at Great Ormond Street Hospital and at
National Hospital for Neurology and Neurosurgery (Lon-
don). Ethical consent for biomarker discovery in NPC was
obtained from NRES Committee South Central – Southamp-
ton A (Ref13/SC/0109) and informed consent was obtained
from all the participants. Blood spots, plasma and random
urine samples from patients with suspected or confirmed disor-
ders of bile acid synthesis were analysed to evaluate the speci-
ficity and selectivity of the proposed test (Table 1).
Sample preparation
Ten microlitres of plasma was spotted onto neonatal
screening cards (Whatman 903™; GE Healthcare Life
Science, Buckinghamshire, UK). The whole sample was
punched out and eluted by sonicating for 15 min with
300 lL of methanol containing the deuterated bile acid
internal standards (concentration: 20 nM).
Blood was collected onto screening cards (Whatman
903™; GE Healthcare Life Science) and allowed to dry
overnight prior to storage in a sealed bag with dessicant at
 80 °C. A 6 mm disc was punched out and sonicated as
described for plasma spots above.
Fifty microlitres of urine was diluted with an equal vol-
ume of methanol containing 20 nM internal standards and
the results were normalized to creatinine concentration [34].
Correlation between NPC bile acids and
oxysterols in plasma
The correlation between the levels of NPCBA1, NPCBA2
and their oxysterol precursors (7-oxocholesterol and choles-
tane-3b,5a,6b-triol) was investigated in eight samples from
untreated NPC1 patients who had had oxysterols analysed
on the same sample [10,33].
Method validation
The method was fully validated, in accordance with the ICH
Q2(R1) guidelines [35], by evaluating accuracy, precision,
limit of detection (LOD), limit of quantitation (LOQ), lin-
earity and matrix effect. Accuracy and precision were
assessed using nine determinations, covering the selected
concentration range (three concentrations/three replicates
each), whereas LOD and LOQ were established by means of
a method based on the calibration curve, where the standard
deviation of y-intercept was used as standard deviation.
Matrix effect(s) were determined by comparing the linearity
of working solutions prepared from extracted human blood/
plasma spots, urine samples to linearity in methanol.
Statistical analysis
Statistical evaluation was performed on the data sets by
Kruskal–Wallis test followed by Dunns, significance
level = 0.05 (*P < 0.05; **P < 0.01; ***P < 0.001).
Results
Synthesis of 3b-hydroxy-7b-N-acetylglucosaminyl-
5-cholenoic acid (NPCBA1) reference standard
and hydrophilic NPCBA1 metabolites
We looked for evidence, in NPC samples, of 3b-
hydroxy-7b-N-acetylglucosaminyl-5-cholenoic acid
(which we called Niemann-Pick C bile acid 1,
NPCBA1). This compound was prepared by solvolysis
[31] of the 3-sulfate [28] and used as a reference stan-
dard for the UPLC-MS/MS analyses. Solvolysis of 3b-
sulfoxy-7b-N-acetyl-glucosaminyl-5-cholenoic acid [28]
produced a bile acid with [MH] of m/z 592, consis-
tent with the expected 3b-hydroxy-7b-N-acetyl-
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Table 1. Retention time, cone voltage, collision energy, precursor and product ion used in identification of normal and abnormal bile acids
detected in healthy participants and in patients with inborn errors of metabolism.
Bile acida
Conjugationb
[Abbreviation]
Retention
time (min)
Cone
voltage (V)
Collision
energy (V)
Precursor
ion (m/z)
Product
ion (m/z)
Chenodeoxycholic acid (3a,7a-diOH-5b) Gly [GCDCA] 1.76 88 31 448.4 74.0
D4-chenodeoxycholic acid Gly [D4-GCDCA] 1.76 88 31 452.4 74.0
Deoxycholic acid (3a,12a-diOH-5b) Gly [GDCA] 1.80 88 33 448.4 74.0
Ursodeoxycholic acid (3a,7b-diOH-5b) Gly [GUDCA] 1.59 88 31 448.4 74.0
Cholic acid (3a,7a,12a-triOH-5b) Gly [GCA] 1.67 86 33 464.4 74.0
D4-cholic acid Gly [D4-GCA] 1.67 86 33 468.4 74.0
Lithocholic acid (3a-OH-5b) Gly [GLCA] 1.86 88 31 432.3 74.0
Chenodeoxycholic acid (3a,7a-diOH-5b) Tau [TCDCA] 1.64 110 59 498.4 80.0
D4-chenodeoxycholic acid Tau [D4-TCDCA] 1.64 110 59 502.4 80.0
Deoxycholic acid (3a,12a-diOH-5b) Tau [TDCA] 1.65 116 59 498.4 80.0
Ursodeoxycholic acid (3a,7b-diOH-5b) Tau [TUDCA] 1.49 110 59 498.4 80.0
Cholic acid (3a,7a,12a-triOH-5b) Tau [TCA] 1.56 116 59 514.4 80.0
D5-cholic acid Tau [D5-TCA] 1.56 116 59 519.4 80.0
Lithocholic acid (3a-OH-5b) Tau [TLCA] 1.72 110 59 482.3 80.0
Chenodeoxycholic acid (3a,7a-diOH-5b) None [CDCA] 1.87 86 5 391.4 391.4
D4-chenodeoxycholic acid None [D4-CDCA] 1.87 86 5 395.4 395.4
Deoxycholic acid (3a,12a-diOH-5b) None [DCA] 1.88 86 5 391.4 391.4
Ursodeoxycholic acid (3a,7b-diOH-5b) None [UDCA] 1.72 86 5 391.4 391.4
Cholic acid (3a,7a,12a-triOH-5b) None [CA] 1.77 86 5 407.4 407.4
D4-cholic acid None [D4-CA] 1.77 86 5 411.4 411.4
Lithocholic acid (3a-OH-5b) None [LCA] 1.97 86 5 375.3 375.3
Hyocholic acid (3a,6a,7a-triOH-5b) None [HCA] 1.72 86 5 407.4 407.4
Hyodeoxycholic acid (3a,6a-diOH-5b) None [HDCA] 1.75 86 5 391.4 391.4
Characteristic of 3b-hydroxy-D5-C27-steroid dehydrogenase deficiency
3b,7a,12a-triOH-D5 None 1.61 86 5 405.3 405.3
3b,7a-diOH-D5 Gly 1.58 88 31 446.0 74.0
3b,7a,12a-triOH-D5 Gly 1.47 86 33 462.0 74.0
3b,7a-diOH-D5 Sulf 1.58 87 32 469.0 97.0
3b,7a,12a-triOH-D5 Sulf 1.47 110 59 485.0 97.0
3b,7a-diOH-D5 Sulf, Gly 1.47 110 59 526.0 97.0
3b,7a,12a-triOH-D5 Sulf, Gly 1.37 86 33 542.0 97.0
3b,7a-diOH-D5 GlcNAc 1.62 80 33 591.9 389.0
Characteristic of D4-3-oxosteroid 5b-reductase deficiency
7a-OH-3-oxo-D4 Gly 1.21 86 33 444.0 74.0
7a,12a-diOH-3-oxo-D4 Gly 1.46 86 33 460.0 74.0
7a-OH-3-oxo-D4 Tau 1.55 110 59 494.0 80.0
7a,12a-diOH-3-oxo-D4 Tau 1.41 110 59 510.0 80.0
Characteristic of oxysterol 7a-hydroxylase deficiency
3b-OH-a5 Sulf, Gly 1.70 86 33 510.0 74.0
Characteristic of Niemann-Pick C
3b,7b-diOH-D5 Gly 1.65 86 33 446.0 74.0
3b,7b-diOH-D5 GlcNAc 1.59 80 33 591.9 389.0
3b,7b-diOH-D5 GlcNAc, Gly 1.44 88 31 649.4 74.0
3b,7b-diOH-D5 GlcNAc, Tau 1.33 116 59 699.4 80.0
3b,7b-diOH-D5 Sulf, GlcNAc 1.48 80 34 672.4 97.0
3b,5a,6b-triOH Gly 1.42 86 33 464.4 74.0
3b,7b,f-triOH-D5 Gly 1.49 86 33 462.4 74.0
a Positions of hydroxyl groups and double bonds in precursor bile acid in brackets. 5b is 5b-cholanoic acid, D5 is 5-cholenoic acid, D4 is 4-
cholenoic acid.
b Gly, glycine; Taur, taurine, Sulf, sulfate; GlucA, glucuronic acid; GlcNAc, N-acetylglucosamine. Abbreviation in square brackets.
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glucosaminyl-5-cholenoic acid and a main product ion
of m/z 389, after the neutral loss of 203 mass units
attributable to the cleavage of the O-GlcNAc bond.
The glycine and taurine conjugates of 3b-hydroxy-
7b-N-acetyl-glucosaminyl-5-cholenoic acid were also
prepared by solvolysis of the respective sulfates [28].
Their mass spectra were characterized by precursor
ions of 649 and 699 m/z and main fragments of 74
and 80 m/z, due to the loss of glycine and taurine
respectively.
Investigation of NPCBA1 accumulation in NPC1
NPCBA1 was one of the major abnormal bile acids
detected in plasma from patients with NPC1. The dif-
ference between the mean plasma concentration in
NPC1 patients and controls was highly significant
(P < 0.001). Nevertheless, a considerable overlap was
observed between some NPC1 patients, NPC1
heterozygotes and controls (Fig. 1A). For two NPC1
patients, in whom the GlcNAc-conjugated bile acid
was undetectable, whole exome sequencing (WES) data
were available. These individuals were found to be
homozygous for the inactivating missense variant
p.C121G (c.T361G) in the UGT3A1 gene, which
encodes the 7b-hydroxy bile acid UDP N-acetylgluco-
saminyl transferase [30]. Conversely, analysis of WES
data from five NPC1 patients whose NPCBA1 levels
were found to be well above the control range,
revealed that two of these individuals were heterozy-
gotes for c.T361G while the others did not carry the
c.T361G UGT3A1 variant.
The urinary excretion of NPCBA1, normalized to
creatinine, was assessed in random urine specimens.
NPCBA1 was markedly increased in most NPC1
patients, showing results above the range for healthy
controls (P < 0.001) (Fig. 1B); however, NPCBA1 was
not increased in the two patients shown by WES to
have the defect in UGT3A1.
Results on dried blood spots confirmed the data
obtained from plasma and urine although levels of
NPCBA1 were below or very close to the LOQ, mak-
ing a precise quantitation impossible.
Urinary excretion of hydrophilic metabolites of
3b,7b-dihydroxy-cholenoic acid and its GlcNAc
conjugate (NPCBA1)
3b,7b-dihydroxy-5-cholenoic acid (derived from7-oxo-
cholesterol) can potentially be modified in a number of
ways leading to increased urinary excretion [28]. These
include conjugations with sulfate in position 3,
GlcNAc in 7, taurine or glycine on the carboxylic
(A)
(B)
Fig. 1. NPCBA1 in dried plasma spots (A) and random urine
samples (B). (A) From left to right: plasma samples from
individuals with NPC1 disease (confirmed by genotyping) but
with unknown UGT3A1 status (n = 73); patients with NPC1 but
also homozygous (n = 2), heterozygous (n = 2) and wild-type
(n = 3) for the T361G (p.C121 > G) mutation/polymorphism in
UGT3A1 that inactivates the GlcNAc transferase, controls
(n = 84) and NPC1 heterozygotes (n = 70). (B) From left to right:
urine samples from individuals with NPC1 disease (confirmed by
genotyping) but with unknown UGT3A1 status (n = 14), patients
with NPC1 but also homozygous for the T361G (p.C121 > G)
mutation/polymorphism in UGT3A1 that inactivates the GlcNAc
transferase (n = 2), controls (n = 10) and NPC1 heterozygotes
(n = 47). Data are expressed as median with interquartile range.
(***P < 0.001).
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group in 24, and the introduction of additional hydro-
xyl groups on the sterane ring (Fig. 2).
These bile acids, being highly conjugated and thus
extremely hydrophilic, were easily quantified by
UPLC-MS/MS in urine of NPC1 patients but were
not detectable or only present in traces in plasma and
blood samples. Specifically, we observed urinary excre-
tion of the following bile acids conjugated to N-acetyl
glucosamine (SRM transitions in square brackets): 3b-
hydroxy-7b-glucosaminyl-5-cholenoic acid (NPCBA1)
[591.9 > 389.0], glycine conjugate of 3b-hydroxy-
7b-glucosaminyl-5-cholenoic acid (NPCBA1-Gly)
[649.4 > 74.0], taurine conjugate of 3b-hydroxy-7b-
glucosaminyl-5-cholenoic acid (NPCBA1-Taur)
[699.4 > 80.0], 3b-sulfoxy-7b-glucosaminyl-5-cholenoic
acid (NPCBA1-Sulf) [672.4 > 97.0] and glycine
conjugate of 3b-sulfoxy-7b-glucosaminyl-5-cholenoic
acid (NPCBA1-Sulf-Gly) [729.4 > 74.0]. Furthermore,
an unsaturated compound (rt 1.49 min) characterized
by the transition [462.4 > 74.0] was found to be ele-
vated in NPC urine compared with controls or
NPC carriers. Although the identity of the com-
pound has not yet been fully established, it could
possibly be the glycine conjugate of a trihydroxy-5-
cholenoic acid and be produced by metabolism of
7-oxocholesterol. When compared with the urinary
measurement of NPCBA1, the pooled measurement
of the 6 bile acids derived from 7-oxocholesterol
demonstrated an improvement in the separation
between NPC1 patients and carriers (P < 0.001) and
between NPC1 patients and controls (P < 0.001)
(Fig. 3).
(A) (A)
(B)
(C)
(D)
(E)
(F)
(B)
Fig. 2. Proposed pathway for the hepatic synthesis of ‘NPC bile acids’. Hepatic formation of NPCBA1, NPCBA1 analogues (left pathway)
and NPCBA2 (right pathway). Endolysosomal accumulation of unesterified cholesterol, associated with cellular oxidative stress (A,B), leads
to the production of oxysterol molecules (7-oxocholesterol and cholestane-3b,5a,6b-triol). The keto group of the 7-oxocholesterol can be
reduced by 7-oxosteroid reductase (C) forming 7b-hydroxycholesterol which, upon further enzymatic modifications, can lead to the series of
NPCBA1 (D) or, alternatively to the formation of a trihydroxycholenoic acid (E). In a similar way, NPCBA2 series can be produced, via
enzymatic reactions (F), from cholestane-3b,5a,6b-triol.
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Investigation of NPCBA2 (probably 3b,5a,6b-
trihydroxycholanoyl-glycine) in biological fluids
from NPC1 patients
In the light of the data obtained for NPCBA1, we
assumed that cholestane-3b,5a,6b-triol would be con-
verted into a bile acid in a similar way to 7-oxocholes-
terol (Fig. 2). The expected cholestane-3b,5a,6b-triol-
derived bile acid is an isomer of cholic acid which
could be further conjugated with glycine or taurine to
produce isomers of glyco- and tauro-cholic acid.
Therefore, we investigated the accumulation of these
hypothesized molecules in biological fluids, via UPLC-
MS/MS. Interesting results were obtained by the
examination of the SRM chromatograms (transitions
in square brackets) of glycocholic acid and isobaric
species [464.4 > 74.0]. As expected, an isobaric species
of glycocholic acid, NPCBA2 (rt 1.44 min compared
with glycocholate 1.67 min) was seen in samples from
NPC patients in greater amounts than in samples from
heterozygotes and controls (Fig. S1A).
Measurement of the plasma level of NPCBA2
(Fig. 4A) demonstrated a significant accumulation in
NPC1 patients compared with NPC1 carriers and
controls. In fact, the plasma concentration of the com-
pound in affected participants (median = 251 nM;
mean = 321 nM) was more than 109 higher than in
healthy controls (median = 20 nM; mean = 21 nM) and
no overlap was observed between the two groups
(P < 0.001). Comparison of the NPC1 patients with the
carriers indicated a small overlap but still a highly sig-
nificant difference between the two groups (P < 0.001).
Similar results have been obtained for dried blood spot
analysis (Fig. 4B), although no overlap between NPC
patients and carriers was observed here (albeit with
smaller numbers). Moreover, a good correlation
(R2 = 0.96) was demonstrated (Fig. S2) between the
amount of NPCBA2 extracted from a 10 lL plasma
spot and a 6 mm blood spot, estimated to contain
12.4 lL of blood [33]. Finally, the analysis of random
urine samples showed a higher urinary excretion of
NPCBA2 in NPC1 patients than in carriers (P < 0.001)
and controls (P < 0.001) but with a small overlap
between the groups, as seen with the plasma results
(panel C, Fig. 4). The plasma concentration of
NPCBA2 (which is produced without GlcNAc conjuga-
tion) was found to be above the control ranges in all
NPC1 patients, including the two with the homozygos-
ity for p.C121G (Fig. 4A), consistent with the hypothe-
sis that the failure to detect an increase in NPCBA1 and
analogues in NPC1 patients can be due to the presence
of a common mutation in the UGT3A1 gene.
Correlation between NPC bile acids and
oxysterols in plasma
The correlations between the levels of NPCBA1 and
NPCBA2 and their putative respective precursors, 7-
oxocholesterol and cholestane-3b,5a,6b-triol, were
assessed on eight plasma samples from untreated
patients (Fig. 5). The oxysterol concentrations in these
samples had been measured by HPLC-MS/MS [10] in
a previous study [32]. The magnitude of the correlation
coefficients were 0.608 and 0.585, respectively, indicat-
ing that the bile acids and oxysterols are moderately
correlated. This result is in keeping with the hypothesis
that NPCBA1 and NPCBA2 are generated by metabo-
lism of oxysterols (Fig. 2). However, Fig. 5A shows
that one patient had elevated 7-oxocholesterol but nor-
mal NPCBA1; the likely explanation is that this
patient had the GlcNAc transferase defect; we did not
have WES data to confirm or refute this. Other factors
that could contribute to the relatively loose correlation
between NPCBA1 and 2 and their oxysterol precursors
include genetic and environmental factors affecting
oxysterol and bile acid metabolism. Cytochrome P450
hydroxylases and sulfatases show genetic variation and
Fig. 3. Urinary excretion of NPCBA1 analogues. Urinary excretion
of NPCBA1 analogues in (from left to right): individuals with NPC1
disease (confirmed by genotyping) but with unknown UGT3A1
status (n = 14), patients with NPC1 but also homozygous for the
T361G (p.C121 > G) mutation/polymorphism in UGT3A1 that
inactivates the GlcNAc transferase (n = 2), controls (n = 10), and
NPC1 heterozygotes (n = 47). Data are expressed as median with
interquartile range. (***P < 0.001). Note: Log scale.
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are inducible by drugs and xenobiotics. Conjugation of
bile acids with taurine as opposed to glycine is affected
by age and diet. Nonetheless, the results strongly sug-
gest that NPCBA1 and NPCBA2 are the main plasma
metabolites of 7-oxocholesterol and cholestane-
3b,5a,6b-triol respectively.
Method validation
The diagnostic method described in this article has
been validated according to the International Confer-
ence of Harmonisation (ICH) guidelines, section Q2
(R1) ‘Validation of analytical procedures: text and
methodology’ [35]. The UPLC-MS/MS identifiers
(retention times, SRM transitions and acquisition
parameters) for the internal standards and compounds
that could be unequivocally identified in patient sam-
ples are listed in Table 1 and summaries of the valida-
tion parameters for quantitation are reported in
Table 2. The method showed a good linearity for all
the analytes over the range 0.1–250 nM, as demon-
strated by the R2 values. Limit of detection (LOD)
and limit of quantitation (LOQ) values were found to
be satisfactory and appropriate for the analysis of the
samples with values lower than 10 nM for urine
(Table 2), equivalent to 300 nM for plasma because of
the 30-fold dilution. As reported in Table 2, the ana-
lytical method is highly accurate, precise and repro-
ducible, with an intra- and interday coefficient of
variation lower than 20% and, in some cases, lower
than 10%. In addition, matrix effects, which can be
observed as ion enhancement or ion suppression, have
been excluded by comparing the linearity of the
(A)
(B)
(C)
Fig. 4. NPCBA2 in dried plasma spots (A), dried blood spots (B)
and random urine samples (C). (A) Concentration (nmolL1) of
NPCBA2 in plasma samples from individuals with NPC1 disease
(confirmed by genotyping) with unknown UGT3A1 status (n = 73),
patients with NPC1 and known UGT3A1 status: homozygous
(n = 2), heterozygous (n = 2) and wild-type (n = 3) for the T361G
(p.C121 > G) mutation/polymorphism in UGT3A1 that inactivates
the GlcNAc transferase, controls (n = 84) and NPC1 heterozygotes
(n = 70). (B) Concentration (nmolL1) of NPCBA2 in dried blood
spots from individuals with NPC1 disease (confirmed by
genotyping) and unknown UGT3A1 status (n = 11), controls (n = 9)
and NPC1 heterozygotes (n = 2). (C) Excretion of NPCBA2
(lmolmmol1 creatinine) in random urine samples from individuals
with NPC1 disease (confirmed by genotyping) with unknown
UGT3A1 status (n = 14), patients with NPC1 but also homozygous
for the T361G (p.C121 > G) mutation/polymorphism in UGT3A1
that inactivates the GlcNAc transferase (n = 2), controls (n = 10)
and NPC1 heterozygotes (n = 47). Data are expressed as median
with interquartile range. (*P < 0.05; ***P < 0.001).
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response in methanol with that obtained in plasma,
blood spots or urine samples (Fig. S3).
Finally, as bile acids are a class of structurally
related molecules sharing the presence of the sterane
nucleus and often differing only in the position or ori-
entation of substituents, the specificity and selectivity
of the diagnostic test were investigated. An efficient
and high-resolution chromatographic separation was
crucial in order to accurately and unequivocally quan-
tify the novel set of bile acids and discriminate
between them and their regio- or stereoisomers, which
are often characteristic of other bile acid-related disor-
ders that can also present initially with cholestatic liver
disease. Samples from patients affected by inborn
errors of bile acid synthesis were used as controls to
exclude a possible misdiagnosis (Table 1). In order to
definitively diagnose NPC, it was essential to distin-
guish between NPCBA2 and its regioisomer glyco-
cholic acid (Fig. S1A), as well as between NPCBA1
and its stereoisomer, 3b-hydroxy-7a-glucosaminyl-5-
cholenoic acid (3b,7a-diOH-D5,GlcNAc conjugate,
Table 1), observed as a minor component of the bile
acid profile in patients with 3b-HSDH deficiency
(Fig. S1B). Indeed, although urinary levels of
NPCBA1 in patients with 3b-HSDH deficiency fell
within the NPC range, the presence of 3b-hydroxy-7a-
glucosaminyl-5-cholenoic acid (rt 1.64 min) was found
to be specifically diagnostic for b-HSDH deficiency.
Retention times of additional isobaric species observed
in different pathological conditions are reported in
Table 1. Furthermore, a full bile acid profile was per-
formed for these samples, in order to evaluate the pos-
sibility of using the proposed UPLC-MS/MS method,
not only for the diagnosis of NPC, but also for the
detection of inborn errors of bile acid synthesis
(Table 1). Some abnormal bile acids needed to be
identified by using patient samples as the source of the
reference compound. As an example: a urine spectrum
from a patient with mutations in AKR1D1 suggested
that a major component was a taurine-conjugated
oxo-dihydroxy-cholenoic acid (precursor ion m/z 510
with major product ion m/z 80). GC-MS analysis, fol-
lowing deconjugation, showed the major bile acid was
7a,12a-dihydroxy-3-oxo-4-cholenoic acid (by
(A)
(B)
Fig. 5. Correlation between NPC bile acids and oxysterols. (A)
Correlation between plasma concentration of NPCBA1 (3b-
hydroxy,7b-N-acetylglucosaminyl-5-cholenoic acid) and its precursor
7-oxocholesterol and (B) between NPCBA2 (3b,5a,6b-
trihydroxycholanoyl-glycine) and cholestane-3b,5a,6b-triol, assessed
on eight samples from untreated NPC patients.
Table 2. Validation results of the UPLC-MS/MS method. Lower
limit of detection (LOD), lower limit of quantitation (LOQ) and
linearity assessed by inter- and intraday R2 values. Accuracy,
precision and intermediate precision assessed at three levels of
concentration (15, 50 and 150 nM).
GCDCA TCDCA GCA TCA
LOD (nM) 2 2 2 2
LOQ (nM) 7 6 8 6
R2 intraday 0.997 0.998 0.997 0.998
R2 interday 0.988 0.995 0.988 0.995
Accuracy % low
level (15 nM)
99 95 98 96
Accuracy % medium
level (50 nM)
93 87 92 91
Accuracy % high
level (150 nM)
98 94 95 90
RDS% precision low
level (15 nM)
1.3 0.5 1.5 1.6
RDS% precision
medium level (50 nM)
0.8 1.4 0.8 2.4
RDS% precision high
level (150 nM)
3.2 2.7 5.1 5.3
RDS% intermediate
precision low level (15 nM)
14.7 6.1 6.9 3.5
RDS% intermediate
medium level (50 nM)
16.5 4.7 3.3 2.7
RDS% intermediate
high level (150 nM)
9.1 3.6 8.0 6.0
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comparing with the synthesised compound). The reten-
tion time and optimized MS/MS parameters of the
compound in this urine sample were used to identify
taurine-conjugated 7a,12a-dihydroxy-3-oxo-4-cholenoic
acid in subsequent UPLC-MS/MS analyses.
Discussion
Mutations in the NPC1 gene usually cause a severe
neurodegenerative disorder associated with cholestatic
liver disease during infancy and persistent splenome-
galy. Although diagnostic tests are currently available,
sample collection, handling and analysis are not quick
and simple; this combined with a variety of clinical
presentations contributes to the diagnostic delay. To
increase the chances that treatment will prevent the
devastating neurological manifestations, it is vital to
develop sensitive diagnostic methods that can be
applied to samples that are easily obtained and easily
sent to the reference laboratory. This article demon-
strates the potential diagnostic value of novel bile
acids derived from hepatic metabolism of 7-oxocholes-
terol and cholestane-3b,5a,6b-triol, as depicted in
Fig. 2. The 7-oxocholesterol family comprises
NPCBA1 (3b-hydroxy-7b-N-acetyl-glucosaminyl-5-cho-
lenoic acid), conjugated forms of this bile acid (3b-
hydroxyl group conjugated to sulfate and/or carboxyl
group amidated with glycine or taurine) and a trihy-
droxycholenoic acid (precise structure not yet deter-
mined) present as the glycine conjugate. Measurement
of NPCBA1 in a dried plasma/blood spot or a random
urine sample is a useful rapid screening test for NPC1
but a ‘false-negative’ result can be obtained for NPC1
patients who are homozygous for the missense poly-
morphism/mutation p.C121G (c.T361G) in UGT3A1
because these patients cannot make GlcNAc-conju-
gated bile acids. Although measurement in urine of all
the 7-oxocholesterol derived bile acids produces good
separation of the majority of NPC1 patients from con-
trols and NPC1 heterozygotes, as do analyses of
NPCBA1 in plasma and dried blood spots, the
UGT3A1 variant homozygotes are not differentiated
from controls. However, quantitation of NPCBA2 (the
bile acid derived from cholestane-3b,5a,6b-triol,
3b,5a,6b-trihydroxy-cholanoyl glycine) in a dried
plasma/blood spot is capable of complete separation
between NPC1 patients and controls, although there is
some overlap with NPC1 heterozygotes. The results
obtained for patients whose whole exome sequencing
data were available indicated that there are no false-
negative results for the UGT3A1 variant homozygotes
when NPCBA2 is assayed. If a patient has a high sus-
picion index for NPC but normal level of NPCBA1,
genetic testing could be carried out to look for the
UGT3A1 mutation.
One of the main advantages of the proposed
method, when compared with existing tests, is the sta-
bility of the analytes in blood spots, plasma spots (for
stored samples) and urine samples. Thus, they can be
obtained easily and transported easily to the analyti-
cal laboratory. A serious potential problem for oxys-
terol analysis is that blood and plasma samples
contain large amounts of cholesterol which can be
converted to 7-oxocholesterol and cholestane-
3b,5a,6b-triol by ex vivo auto-oxidation; there is no
potential precursor of the abnormal bile acids that
could give rise to them outside the body. The pro-
posed test, fully validated in accordance to the ICH
Q2(R1) guidelines, is suitable not only for NPC, but
for the simultaneous and selective determination of a
variety of structurally related bile acids and thus for
the diagnosis and treatment monitoring of several bile
acid disorders.
This simple single step assay involving extraction of
bile acids from dried blood or plasma spots by means
of a 15 min sonication or simple dilution of urine sam-
ples is suitable for translation into routine clinical
diagnostic laboratories being both robust and versatile,
(capable of accurately and precisely measuring analytes
over the concentration range of three orders of magni-
tude) as well as being rapid (UPLC run: 3.5 min) and
cost-effective. The simplified protocols make it possible
not only to reduce turnaround times and increase the
sample throughput, but also minimize experimental
bias and human error.
Ideally, before being used clinically, a diagnostic test
should be subjected to external validation; however, in
the case of a rare disease such as NPC (incidence 1 in
100 000), it will take a considerable amount of time to
collect samples for a validation set; the derivation data
included 73 samples from untreated NPC patients col-
lected from both Europe and USA over a period of
2 years.
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